Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts
Main finding · Major limb eventsResult — go to the resultHazard ratio 0.77 95% CI 0.61–0.97Authors' conclusion
Among people with type 2 diabetes and PAD or foot ulcers, the use of semaglutide was associated with a significantly lower risk of major limb events than other GLTs.
Study context
- Population
- Adults with T2D and peripheral artery disease (PAD) or foot ulcers, new users of diabetes medications; 57% male, age 61 years, 12-year diabetes duration, baseline HbA1c 8.0%, body mass index (BMI) 31 kg/m²matched cohort
- Participants
- 167 vs 167
- Exposure
- Semaglutide vs other glucose-lowering therapies (GLT)
- Semaglutiden = 167
- GLTn = 167reference
- Outcome
- Major limb events:
- Peripheral PTA
- Critical limb ischaemia
- Follow-up
- Median 30.1 months
Methodological detailssingle-centre, new users, propensity score matched
- Single-centre
- New users
- Propensity score matched
Main finding
Major limb events
Hazard ratio
0.77
95% CI 0.61–0.97
P = 0.029
Events by group
Semaglutidevs GLT
HR 0.77 (95% CI 0.61–0.97); P = 0.029
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| LEA (major and minor)50% lower with semaglutide | 0.50 (0.30–0.83) | P = 0.008 | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts. Diabetes Obes Metab. Published 7 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →